Hear the latest groundbreaking news in Alzheimer’s research: Sinaptica, a member of StartUp Health’s Alzheimer’s Moonshot Community, has announced significant results from its Phase 2 clinical trial testing the company’s noninvasive, personalized, precise neuromodulation designed to stop the progression of Alzheimer’s disease.
Ken Mariash, CEO of Sinaptica, joined us in the StartUp Health Studio at HLTH 2024 to break it all down for us. As you’ll hear, the interview took place prior to the release of this data, which became public on October 31.
In this exclusive interview, you’ll learn:
✓ Details on Sinaptica’s Phase 2 trial results show significant promise in slowing Alzheimer’s progression
✓ The science behind Sinaptica’s technology
✓ How personalized neuromodulation is revolutionizing brain health
✓ The potential for proactive brain strengthening and repair
✓ The impact on patients’ daily lives
✓ The future of Alzheimer’s treatment
---
Apply to Join a Health Moonshot Community: www.startuphealth.com/
Connect with StartUpHealth:
Website: www.startuphealth.com/
Instagram: www.instagram.com/startuphealth/
Twitter: twitter.com/startuphealth
Podcast: startup-health-now.blubrry.net/
StartUp Health